APUS · Apimeds Pharmaceuticals US, Inc. · Exempt Offerings
$1.83
+0.16 (+9.58%)
At close · Sep 18
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.47M
Shares
1.51M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
No Exempt Offerings
No Form D exempt-offering notices are available for this stock yet.